Prochieve 8%, approved for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and secondary amenorrhea;
Prochieve 4%, approved for secondary amenorrhea;
Advantage-S, a spermicidal contraceptive;
RepHresh Vaginal Gel, a feminine hygiene product.

In addition to providing overall direction to the commercialization program, Columbia will be responsible for distribution, regulatory and medical affairs, marketing and all product manufacturing. Columbia expects to launch these women's healthcare products commencing in the third quarter of 2002.

Quintiles' strategic investment group, PharmaBio Development, will invest $4.5 million, to be paid in four equal quarterly installments commencing third quarter 2002 in return for a 5% royalty on the net sales of Columbia's women's healthcare products in the United States for five years beginning in the first quarter of 2003. The royalty payments are subject to minimum and maximum amounts. PharmaBio also has purchased $5.5 million in Columbia stock at the current market price.

Columbia's President and Chief Executive Officer Fred Wilkinson, said: "This agreement gives us the immediate capability to initiate sales and marketing activities for our expanding line of women's healthcare products with efforts focused on targeted obstetricians and gynecologists in the United States. We're very pleased to be working with Innovex and their successful product promotion team, as well as PharmaBio, based upon their creative ability to support our commercialization plans. This joint relationship is an important step for Columbia towards establishing a growing revenue base and a future earnings stream."

Ron Wooten, President, PharmaBio Development, said the agreement with Columbia is another example "in which PharmaBio is able to work with customers to provide creative, strategic solutions to their needs. This is a new model for our industry, and we are finding real demand for our strategic and financial offerings in the marketplace. We are excited about supporting Columbia in their marketing efforts for Prochieve and other products to obstetricians and gynecologists."

About Quintiles
Quintiles Transnational helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, N.C., Quintiles is a member of the S&P 500 and Fortune 1000. For more information, visit the company's Web site at www.quintiles.com.

PharmaBio Development, the corporate ventures group of Quintiles Transnational Corp., is dedicated to innovative partnering solutions for pharmaceutical and biotech companies. Innovex, the world's leading commercial solutions provider, offers a unique array of sales and marketing services designed to accelerate the success of pharmaceutical, biotech and medical device products. For more information, visit www.innovex.com.

About Columbia
Columbia Laboratories, Inc. is an international pharmaceutical company whose mission is to provide new and better ways to meet the special health needs of people around the world. To achieve this objective, the Company is developing and has commercialized innovative prescription and over-the-counter pharmaceutical products that address the unique healthcare needs and endocrinology issues of women, including formulations that treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. The Company is also developing innovative new hormonal products for men, as well as an exciting new buccal peptide delivery system. For more information, visit www.columbialabs.com.

This press release contains forward-looking statements regarding Quintiles and Columbia that involve risks and uncertainties that could cause actual results to differ materially. The risks and uncertainties with respect to Quintiles include, without limitation, the risk that the market for Quintiles' products and services will not grow as expected, the risk that PharmaBio transactions will not generate revenues or profit at the rate or levels anticipated, Quintiles' ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. The risks and uncertainties with respect to Columbia include, without limitation, the successful marketing reintroduction of Crinone by Serono, the successful launch and marketing of Prochieve, RepHresh Vaginal Gel, and Advantage-S, the timely and successful development of products, timely and successful completion of clinical studies, success in obtaining FDA acceptance and approval of new products, and competitive economic and regulatory factors in the pharmaceutical and healthcare industry. Additional factors that could cause actual results to differ materially are discussed in Quintiles' and Columbia's recent filings with the Securities and Exchange Commission, including but not limited to each company's Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.